Definium's LSD Pill Eases Anxiety in Phase 3 Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Definium Therapeutics said its LSD-based therapy DT120 significantly eased generalized anxiety disorder versus placebo in a Phase 3 study of 214 patients who received a single dose.
- The trial randomized 214 patients to receive either one dose of DT120 or placebo, and this is the first of two large Phase 3 studies Definium is running in anxiety.
- DT120 is described by Definium as a "proprietary, pharmaceutically optimized" LSD pill, distinguishing it from unformulated LSD.
- The anxiety readout is Definium's second major Phase 3 win in two months, following a previously reported Phase 3 success in major depression.
- The announcement was made Wednesday and positions DT120 within a broader push of psychedelic-derived candidates advancing into late-stage testing for psychiatric conditions.
Why it matters: Two back-to-back Phase 3 wins — first in depression, now anxiety — make Definium one of the more advanced psychedelic-drug developers, and a successful single-dose regimen would be commercially notable because it differentiates the product from chronic-daily psychiatric drugs that dominate the anxiety market today.
Ask SkimNews
